Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Alphabet's Calico Inks $571M Deal with Mabwell for Anti-Aging Asset

Calico Life Sciences, a biotech company under Alphabet's umbrella, has entered into a significant licensing agreement with China-based Mabwell Bioscience. The deal, potentially worth up to $571 million, centers around investigational IL-11 directed therapeutics, including a promising clinical-stage monoclonal antibody for age-related diseases.

NoahAI News6/27/2025

Novo Nordisk Expands Wegovy Access Through WeightWatchers Partnership, Terminates Hims & Hers Deal

Novo Nordisk, the pharmaceutical giant behind the blockbuster weight loss drug Wegovy, has announced a new partnership with WeightWatchers to broaden access to its popular medication. This strategic move comes on the heels of the company's recent decision to terminate its partnership with telehealth provider Hims & Hers, highlighting the complex landscape of weight loss drug distribution and the pharmaceutical industry's efforts to navigate it.

NoahAI News6/27/2025

Abbott Expands Global Footprint with Abu Dhabi Partnership, Highlighting Pharmaceutical Industry's Middle East Focus

U.S. multinational company Abbott has entered into a strategic partnership with Abu Dhabi's Department of Health, marking a significant development in the pharmaceutical industry's growing presence in the Middle East. The collaboration, announced during the recent BIO International Convention in Boston, aims to establish local production of Abbott's pharmaceutical catalog in the United Arab Emirates capital.

NoahAI News6/26/2025

Altimmune's GLP-1/Glucagon Agonist Shows Mixed Results in Phase 2 MASH Trial

Altimmune's pemvidutide, a GLP-1/glucagon dual receptor agonist, has demonstrated a mix of promise and setbacks in a recent phase 2 trial for metabolic dysfunction-associated steatohepatitis (MASH). The study results, while highlighting the drug's potential in weight loss, have led to a significant drop in the company's stock price.

NoahAI News6/26/2025

Healthcare Industry Faces Layoffs Amid Financial Pressures and Regulatory Uncertainty

UC San Diego Health has laid off approximately 230 workers, representing about 1.5% of its workforce, in response to mounting financial pressures and regulatory uncertainty. The healthcare provider cited rising costs of care and inadequate reimbursement rates from Medicare, Medicaid, and insurers as key factors behind the decision.

NoahAI News6/26/2025

Pfizer's Hympavzi Shows Promise in Hemophilia Patients with Inhibitors

Pfizer's hemophilia drug Hympavzi has demonstrated effectiveness in a new group of patients, potentially paving the way for a label expansion. The pharmaceutical giant announced positive top-line results from a phase 3 trial in hemophilia A or B patients classified as "inhibitors," marking a significant development in the treatment landscape for this challenging subset of patients.

NoahAI News6/26/2025

Hummingbird Biosciences Inks $290M Deal with Percheron for VISTA-Targeting Cancer Drug

Hummingbird Biosciences has entered into a lucrative licensing agreement with Percheron Therapeutics for its phase 2-ready cancer drug, HMBD-002. The deal, announced on June 25, 2025, could be worth up to $290 million in upfront and potential milestone payments.

NoahAI News6/26/2025

Tandem Diabetes Care Expands Partnerships and Product Pipeline in Diabetes Tech Sector

Tandem Diabetes Care, a leading player in the diabetes technology market, has announced significant developments in its product lineup and strategic partnerships. The company's recent moves aim to broaden its reach and provide more options for people with diabetes, particularly those who have not yet adopted insulin pump therapy.

NoahAI News6/26/2025

Pharmaceutical Industry Faces Widespread Layoffs Amid Strategic Shifts

The pharmaceutical and biotech sectors are experiencing a wave of workforce reductions and strategic realignments as companies adapt to challenging market conditions and reprioritize their pipelines.Novartis is laying off 427 employees at its U.S. headquarters in East Hanover, New Jersey, with the cuts taking place from June to October. This follows the company's December 2024 decision to let go of 330 employees as part of closing sites in Germany and Boston acquired from MorphoSys.

NoahAI News6/26/2025

Uncovering Hidden Opportunities in the Biopharma Job Market

In today's competitive pharmaceutical and biotech industry, job seekers are increasingly turning to unconventional methods to secure their next role. A recent report highlights the growing importance of tapping into the "hidden job market" – positions that aren't publicly advertised but represent significant opportunities for career advancement.

NoahAI News6/26/2025

Kymera Therapeutics Expands Partnerships with Gilead and Sanofi, Advancing Protein Degradation Technology

Kymera Therapeutics, a pioneer in targeted protein degradation, has announced significant developments in its partnerships with pharmaceutical giants Gilead Sciences and Sanofi. These collaborations mark important advancements in the field of molecular glue degraders and protein degradation technology, with potential implications for oncology and immunology treatments.

NoahAI News6/26/2025

FDA Investigates Patient Deaths Following Sarepta's DMD Gene Therapy Elevidys

The U.S. Food and Drug Administration (FDA) has launched an investigation into Sarepta Therapeutics' Duchenne muscular dystrophy (DMD) gene therapy Elevidys following reports of two patient deaths. The agency is evaluating the need for further regulatory action, potentially reshaping the landscape for gene therapies in rare diseases.

NoahAI News6/26/2025

«1...5 6 7...67 »